Adc Therapeutics Sa (ADCT)

$3.73 +0.01 (0.27%)
Market Cap 472.60M
Revenue (ttm) 81.36M
Net Income (ttm) -142.62M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -175.30%
Debt to Equity Ratio -0.62
Volume 541,600
Avg Vol 852,020
Day's Range N/A - N/A
Shares Out 127.04M
Stochastic %K 46%
Beta 1.94
Analysts Strong Sell
Price Target $8.00

Company Profile

ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform in Switzerland and the United States. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration, conditional approval from the European Commission, and conditional approval from the China National Medical Products Administration for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemi...

Industry: Biotechnology
Sector: Healthcare
Phone: 41 21 653 02 00
Address:
BiopOle, Route de la Corniche 3B, Epalinges, Switzerland
SamHot
SamHot Apr. 7 at 1:36 PM
$ADCT HOLD TIGHT
0 · Reply
focafoca99
focafoca99 Apr. 1 at 9:48 PM
$ADCT granted a new employee inducement option covering 17,000 shares.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Mar. 24 at 1:40 AM
$ADCT RSI: 50.00, MACD: 0.0004 Vol: 0.25, MA20: 4.22, MA50: 3.99 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
erevnon
erevnon Mar. 23 at 11:36 AM
HC Wainwright & Co. maintains ADC Therapeutics $ADCT at Buy and raises the price target from $7 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
SamHot
SamHot Mar. 12 at 3:03 PM
$ADCT opportunity to buy a little more
0 · Reply
Gabriel_DS
Gabriel_DS Mar. 12 at 2:31 PM
$ADCT did I miss something? Don't say market
0 · Reply
fmalad
fmalad Mar. 12 at 5:04 AM
$ADCT lotus 5 we go to 10 buyout before lotus 7 we go to 28. Buyout after lotus 7 we go 30-35. No partnership. Hedge fund owners want cash offer!
1 · Reply
scalpemfast
scalpemfast Mar. 12 at 1:59 AM
$ADCT , $AMD, $NVDA ADCT needs to be on your screen . It’s growing !!!
0 · Reply
scalpemfast
scalpemfast Mar. 12 at 1:56 AM
$ADCT let’s get over $5 and open it up a little. Get on the gas !!!⛽️
0 · Reply
scalpemfast
scalpemfast Mar. 11 at 2:08 AM
$ADCT buyout
0 · Reply
Latest News on ADCT
ADC Therapeutics Announces New Employee Inducement Grant

Apr 1, 2026, 4:05 PM EDT - 7 days ago

ADC Therapeutics Announces New Employee Inducement Grant

ADC Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Operational Update

Mar 10, 2026, 7:30 AM EDT - 4 weeks ago

ADC Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Operational Update

ADC Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call on March 10, 2026

Mar 3, 2026, 7:15 AM EST - 5 weeks ago

ADC Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call on March 10, 2026

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

Mar 2, 2026, 4:05 PM EST - 5 weeks ago

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

ADC Therapeutics to Participate in March Investor Conferences

Feb 24, 2026, 7:15 AM EST - 6 weeks ago

ADC Therapeutics to Participate in March Investor Conferences

ADC Therapeutics Announces Amended HealthCare Royalty Financing Agreement

Feb 23, 2026, 7:15 AM EST - 6 weeks ago

ADC Therapeutics Announces Amended HealthCare Royalty Financing Agreement

ADC Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Revenue and Cash Estimates and Recent Corporate Updates

Jan 8, 2026, 4:05 PM EST - 3 months ago

ADC Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Revenue and Cash Estimates and Recent Corporate Updates

ADC Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Jan 8, 2026, 7:15 AM EST - 3 months ago

ADC Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference

ADC Therapeutics Announces Updated Data from LOTIS-7 Phase 1b Clinical Trial of ZYNLONTA® in Combination with Bispecific Antibody Supporting Potential Best-in-Class Regimen in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma

Dec 3, 2025, 7:30 AM EST - 4 months ago

ADC Therapeutics Announces Updated Data from LOTIS-7 Phase 1b Clinical Trial of ZYNLONTA® in Combination with Bispecific Antibody Supporting Potential Best-in-Class Regimen in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma

ADC Therapeutics to Provide Update on LOTIS-7 Clinical Trial

Dec 2, 2025, 4:05 PM EST - 4 months ago

ADC Therapeutics to Provide Update on LOTIS-7 Clinical Trial

ADC Therapeutics Reports Third Quarter 2025 Financial Results and Provides Operational Update

Nov 10, 2025, 7:30 AM EST - 5 months ago

ADC Therapeutics Reports Third Quarter 2025 Financial Results and Provides Operational Update

ADC Therapeutics to Host Third Quarter 2025 Financial Results Conference Call on November 10, 2025

Nov 3, 2025, 7:15 AM EST - 5 months ago

ADC Therapeutics to Host Third Quarter 2025 Financial Results Conference Call on November 10, 2025

ADC Therapeutics to Present at November Investor Conferences

Oct 27, 2025, 7:15 AM EDT - 5 months ago

ADC Therapeutics to Present at November Investor Conferences

ADC Therapeutics Announces $60 Million Private Placement

Oct 13, 2025, 7:30 AM EDT - 6 months ago

ADC Therapeutics Announces $60 Million Private Placement

ADC Therapeutics to Present at the Cantor Global Healthcare Conference 2025

Aug 27, 2025, 7:15 AM EDT - 8 months ago

ADC Therapeutics to Present at the Cantor Global Healthcare Conference 2025

ADC Therapeutics Reports Second Quarter 2025 Financial Results and Provides Operational Update

Aug 12, 2025, 7:30 AM EDT - 8 months ago

ADC Therapeutics Reports Second Quarter 2025 Financial Results and Provides Operational Update

ADC Therapeutics to Host Second Quarter 2025 Financial Results Conference Call on August 12, 2025

Aug 5, 2025, 4:05 PM EDT - 8 months ago

ADC Therapeutics to Host Second Quarter 2025 Financial Results Conference Call on August 12, 2025

ADC Therapeutics Makes Grant to New Employee Under Inducement Plan

Jul 1, 2025, 4:05 PM EDT - 10 months ago

ADC Therapeutics Makes Grant to New Employee Under Inducement Plan

ADC Therapeutics Announces Updated ZYNLONTA® Investigator-Initiated Trial Data in R/R Marginal Zone Lymphoma Presented at 18th International Conference on Malignant Lymphoma (ICML)

Jun 16, 2025, 7:15 AM EDT - 10 months ago

ADC Therapeutics Announces Updated ZYNLONTA® Investigator-Initiated Trial Data in R/R Marginal Zone Lymphoma Presented at 18th International Conference on Malignant Lymphoma (ICML)

ADC Therapeutics Announces $100 Million Private Placement Extending Expected Cash Runway into 2028

Jun 12, 2025, 6:45 AM EDT - 10 months ago

ADC Therapeutics Announces $100 Million Private Placement Extending Expected Cash Runway into 2028

ADC Therapeutics Announces Updated Data from LOTIS-7 Clinical Trial Presented at the European Hematology Association 2025 Congress

Jun 12, 2025, 6:30 AM EDT - 10 months ago

ADC Therapeutics Announces Updated Data from LOTIS-7 Clinical Trial Presented at the European Hematology Association 2025 Congress

ADC Therapeutics to Present at Upcoming Investor Conferences

May 15, 2025, 7:15 AM EDT - 11 months ago

ADC Therapeutics to Present at Upcoming Investor Conferences

ADC Therapeutics Reports First Quarter 2025 Financial Results and Provides Operational Update

May 14, 2025, 8:00 AM EDT - 11 months ago

ADC Therapeutics Reports First Quarter 2025 Financial Results and Provides Operational Update

ADC Therapeutics Announces Presentation of LOTIS-7 Clinical Trial Data at the European Hematology Association 2025 Congress (EHA2025) and the 18th International Conference on Malignant Lymphoma (ICML)

May 14, 2025, 7:45 AM EDT - 11 months ago

ADC Therapeutics Announces Presentation of LOTIS-7 Clinical Trial Data at the European Hematology Association 2025 Congress (EHA2025) and the 18th International Conference on Malignant Lymphoma (ICML)

ADC Therapeutics to Host First Quarter 2025 Financial Results Conference Call on May 14, 2025

May 8, 2025, 7:15 AM EDT - 11 months ago

ADC Therapeutics to Host First Quarter 2025 Financial Results Conference Call on May 14, 2025

ADC Therapeutics Announces Preclinical Data Highlighted at the American Association for Cancer Research Annual Meeting 2025

Apr 28, 2025, 7:00 AM EDT - 1 year ago

ADC Therapeutics Announces Preclinical Data Highlighted at the American Association for Cancer Research Annual Meeting 2025

ADC Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

Apr 1, 2025, 7:15 AM EDT - 1 year ago

ADC Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

ADC Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Operational Update

Mar 27, 2025, 7:30 AM EDT - 1 year ago

ADC Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Operational Update

ADC Therapeutics Announces Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting 2025

Mar 25, 2025, 5:30 PM EDT - 1 year ago

ADC Therapeutics Announces Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting 2025

ADC Therapeutics to Host Fourth Quarter and Year-End 2024 Financial Results Conference Call on March 27, 2025

Mar 20, 2025, 7:15 AM EDT - 1 year ago

ADC Therapeutics to Host Fourth Quarter and Year-End 2024 Financial Results Conference Call on March 27, 2025

ADC Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference

Jan 30, 2025, 7:15 AM EST - 1 year ago

ADC Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference

ADC Therapeutics Announces Completion of Enrollment of Phase 3 Confirmatory Clinical Trial of ZYNLONTA® in Combination with Rituximab in 2L+ Diffuse Large B-Cell Lymphoma

Dec 30, 2024, 4:30 PM EST - 1 year ago

ADC Therapeutics Announces Completion of Enrollment of Phase 3 Confirmatory Clinical Trial of ZYNLONTA® in Combination with Rituximab in 2L+ Diffuse Large B-Cell Lymphoma

ADC Therapeutics Announces Positive Initial Data from LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Bispecific Antibody in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma

Dec 11, 2024, 7:30 AM EST - 1 year ago

ADC Therapeutics Announces Positive Initial Data from LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Bispecific Antibody in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma

ADC Therapeutics Announces The Lancet Haematology Publication of Data from Investigator-Initiated Trial Evaluating ZYNLONTA® in Combination with Rituximab to Treat Relapsed/Refractory Follicular Lymphoma

Dec 9, 2024, 7:30 AM EST - 1 year ago

ADC Therapeutics Announces The Lancet Haematology Publication of Data from Investigator-Initiated Trial Evaluating ZYNLONTA® in Combination with Rituximab to Treat Relapsed/Refractory Follicular Lymphoma

ADC Therapeutics to Provide Initial Data Update on LOTIS-7 Clinical Trial

Dec 6, 2024, 7:30 AM EST - 1 year ago

ADC Therapeutics to Provide Initial Data Update on LOTIS-7 Clinical Trial

ADC Therapeutics Faces Competitive Oncology Market But Analyst Sees 100% Upside - Here's Why

Nov 8, 2024, 1:14 PM EST - 1 year ago

ADC Therapeutics Faces Competitive Oncology Market But Analyst Sees 100% Upside - Here's Why

ADC Therapeutics Reports Third Quarter and Year-to-Date 2024 Financial Results and Provides Operational Update

Nov 7, 2024, 7:30 AM EST - 1 year ago

ADC Therapeutics Reports Third Quarter and Year-to-Date 2024 Financial Results and Provides Operational Update

ADC Therapeutics Announces Investigator-Initiated Study Abstracts Accepted for Presentation at the 66th ASH Annual Meeting

Nov 5, 2024, 9:47 AM EST - 1 year ago

ADC Therapeutics Announces Investigator-Initiated Study Abstracts Accepted for Presentation at the 66th ASH Annual Meeting

ADC Therapeutics to Host Third Quarter 2024 Financial Results Conference Call on November 7, 2024

Oct 31, 2024, 7:15 AM EDT - 1 year ago

ADC Therapeutics to Host Third Quarter 2024 Financial Results Conference Call on November 7, 2024

ADC Therapeutics Reports Second Quarter 2024 Financial Results and Provides Operational Update

Aug 6, 2024, 7:30 AM EDT - 1 year ago

ADC Therapeutics Reports Second Quarter 2024 Financial Results and Provides Operational Update

ADC Therapeutics to Host Second Quarter 2024 Financial Results Conference Call on August 6, 2024

Jul 30, 2024, 7:15 AM EDT - 1 year ago

ADC Therapeutics to Host Second Quarter 2024 Financial Results Conference Call on August 6, 2024

Myricx Bio Announces £90m ($114m) Series A Financing to Advance its Novel NMTi-ADC Therapeutics into Clinical Development

Jul 8, 2024, 2:00 AM EDT - 1 year ago

Myricx Bio Announces £90m ($114m) Series A Financing to Advance its Novel NMTi-ADC Therapeutics into Clinical Development

CG

ADC Therapeutics Set to Join Russell 2000® and Russell 3000® Indexes

Jun 27, 2024, 7:15 AM EDT - 1 year ago

ADC Therapeutics Set to Join Russell 2000® and Russell 3000® Indexes

ADC Therapeutics to Participate in the Jefferies Global Healthcare Conference

May 30, 2024, 7:15 AM EDT - 2 years ago

ADC Therapeutics to Participate in the Jefferies Global Healthcare Conference

ADC Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

May 15, 2024, 7:15 AM EDT - 2 years ago

ADC Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

ADC Therapeutics to Participate in 2024 RBC Capital Markets Global Healthcare Conference

May 9, 2024, 7:15 AM EDT - 2 years ago

ADC Therapeutics to Participate in 2024 RBC Capital Markets Global Healthcare Conference

ADC Therapeutics Announces $105 Million Underwritten Offering of Common Shares and Pre-Funded Warrants

May 6, 2024, 7:30 AM EDT - 2 years ago

ADC Therapeutics Announces $105 Million Underwritten Offering of Common Shares and Pre-Funded Warrants

ADC Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates

May 6, 2024, 6:10 AM EDT - 2 years ago

ADC Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates

SamHot
SamHot Apr. 7 at 1:36 PM
$ADCT HOLD TIGHT
0 · Reply
focafoca99
focafoca99 Apr. 1 at 9:48 PM
$ADCT granted a new employee inducement option covering 17,000 shares.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Mar. 24 at 1:40 AM
$ADCT RSI: 50.00, MACD: 0.0004 Vol: 0.25, MA20: 4.22, MA50: 3.99 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
erevnon
erevnon Mar. 23 at 11:36 AM
HC Wainwright & Co. maintains ADC Therapeutics $ADCT at Buy and raises the price target from $7 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
SamHot
SamHot Mar. 12 at 3:03 PM
$ADCT opportunity to buy a little more
0 · Reply
Gabriel_DS
Gabriel_DS Mar. 12 at 2:31 PM
$ADCT did I miss something? Don't say market
0 · Reply
fmalad
fmalad Mar. 12 at 5:04 AM
$ADCT lotus 5 we go to 10 buyout before lotus 7 we go to 28. Buyout after lotus 7 we go 30-35. No partnership. Hedge fund owners want cash offer!
1 · Reply
scalpemfast
scalpemfast Mar. 12 at 1:59 AM
$ADCT , $AMD, $NVDA ADCT needs to be on your screen . It’s growing !!!
0 · Reply
scalpemfast
scalpemfast Mar. 12 at 1:56 AM
$ADCT let’s get over $5 and open it up a little. Get on the gas !!!⛽️
0 · Reply
scalpemfast
scalpemfast Mar. 11 at 2:08 AM
$ADCT buyout
0 · Reply
scalpemfast
scalpemfast Mar. 11 at 1:39 AM
$ADCT buyout coming
1 · Reply
Nerevarine
Nerevarine Mar. 10 at 5:27 PM
$ADCT Finally some good price action for this stellar company been in this for a while
0 · Reply
Rox22
Rox22 Mar. 10 at 1:16 PM
$ADCT good call. Revenues up, costs down (and projected to decrease as studies wrap up). Data looks to be on timeline. Biggest take is of data goes well the market share they predict is very conservative, 10% of second line patients, which is why they have as a mini therapy currently. If data is differentiating (which the current numbers are) could be much higher % of second treatment protocols and the 600M-1billion opportunity could be much higher. Smart they are conservative, but they will adjust once they get the actual top line data. Good call! Suggest you read the transcript if you are invested here.
1 · Reply
StocktwitsEarnings
StocktwitsEarnings Mar. 10 at 12:06 PM
$ADCT Q4 '25 Earnings Results & Recap • Reported GAAP EPS of -$0.04 up 86.21% YoY • Reported revenue of $23.06M up 36.36% YoY • ADC Therapeutics expects topline LOTIS-5 results in 2Q 2026, with full data for LOTIS-5 and LOTIS-7 by year-end 2026, and anticipates cash runway at least into 2028, supporting potential regulatory approval for LOTIS-5 in mid-2027.
0 · Reply
fmalad
fmalad Mar. 10 at 4:45 AM
$ADCT earnings should be inline tomorrow. Maybe to the upside!
0 · Reply
Arcides
Arcides Mar. 5 at 6:32 PM
$ADCT every breakout attempt on last month has failed miserably...
2 · Reply
CrackheadApparel
CrackheadApparel Mar. 5 at 2:55 PM
$ADCT I firmly believe that this will be one of the last with a $4 price.
0 · Reply
fort_worth_Jason
fort_worth_Jason Mar. 2 at 9:50 PM
$ADCT ADC Therapeutics is clearing gearing up for expanded use. Good time to get stock options!
0 · Reply
fort_worth_Jason
fort_worth_Jason Mar. 2 at 7:00 PM
$ADCT I would not be surprised if ADC Therapeutics is purchased by another company prior to these results. Once the results are shared the company becomes significantly more valuable. I am confident that is why we are seeing some the recent events. Hold tight and load up more if you can.
0 · Reply
SamHot
SamHot Feb. 25 at 7:41 PM
$ADCT buy buy N BUY
0 · Reply
Rox22
Rox22 Feb. 23 at 5:05 PM
$ADCT @fort_worth_Jason The agreement today essential trades 225 Million in the buyout agreement for 9.8 Million warrants executable at $3.81 share price. In order for that to break even I’m showing a potential buyout share price would have to be at $22.89 making the market cap 2.8 Billion (the buyout would be north of 3B dude to debt/agreemnt liabilities). That would be a reasonable buyout but HealthCare Royalty might know it’s higher like your 5B estimate as to risk the 225M they would potentially want more upside. This could happen quick in the current market for deals. Let’s hope so! LFG!!! Would LOVE a multi-Billion dollar buyout!
1 · Reply
Rox22
Rox22 Feb. 23 at 2:51 PM
$ADCT When and do how much is the question. Would think it would occur after the readouts of Lotus 5 & 7 later this year but this news announcement could be indicating much sooner. My thought was a 2-4B buyout in the long run. I would think they would have more leverage after the readouts but perhaps they have good suitors knocking right now on their door. Fingers crossed.
1 · Reply